NCT05263908View on ClinicalTrials.gov

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

CompletedOBSERVATIONAL

Enrollment

3,346

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions

SARS-CoV-2 Infection

Interventions

DRUG

nirmatrelvir / ritonavir

The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.

Trial Locations (1)

1518589

Pfizer Local County, Tokyo